Theranostic approaches in oncology and Radionuclide therapy, we are looking for consortium

Dr. Demet Nak is a dedicated nuclear medicine physician with a strong clinical and academic background in hybrid imaging, targeted radionuclide therapies, and personalized treatment approaches. She currently works at Recep Tayyip Erdoğan University Training and Research Hospital, where she actively contributes to both diagnostic and therapeutic nuclear medicine practices.

Her clinical experience includes advanced imaging techniques such as FDG PET/CT, Ga-68 PSMA PET/CT, Ga-68 DOTA- PET/CT, and SPECT-based scintigraphy. In addition, she is directly involved in the planning and execution of targeted radionuclide therapies, including radioactive iodine (RAI), Lutetium-177 PSMA, Lutetium-177 DOTATATE, and transarterial radioembolization (TARE).

Throughout her career, Dr. Nak has maintained a strong interest in the integration of imaging and therapy—a core principle of theranostics. She has focused on utilizing functional imaging not only for diagnosis and staging but also for evaluating treatment response and guiding clinical decision-making. Her work with FLT PET/CT, particularly in assessing early therapeutic response in liver tumors, reflects her commitment to improving patient outcomes through innovative imaging strategies.

Dr. Nak’s recent research includes the use of artificial intelligence and machine learning to predict treatment responses in differentiated thyroid cancer and metastatic castration-resistant prostate cancer. She believes that data-driven models, when combined with molecular imaging parameters, have the potential to personalize therapy in a meaningful way.

In addition to her ongoing projects, she is intellectually invested in the future role of liquid biopsy in nuclear medicine. While she has not yet conducted direct research in this area, she is keen to explore how circulating biomarkers might be integrated with molecular imaging for early prediction and monitoring of therapy response.

She has published over 20 peer-reviewed SCI-indexed articles and has delivered numerous oral presentations at national and international congresses. Her academic vision is driven by a desire to bridge clinical practice with translational research, with the ultimate goal of advancing precision medicine in oncology.

Key Interests and Expertise:

• Hybrid molecular imaging: FDG PET/CT, Ga-68 PSMA, Ga-68 DOTATATE, FLT PET/CT

• Theranostic approaches in oncology

• Radionuclide therapy: RAI, Lu-177 PSMA, Lu-177 DOTATATE, TARE

• Personalized dosimetry and response prediction

• Machine learning applications in nuclear medicine

• Future potential of liquid biopsy in imaging-biomarker integration